靶向CCL2-CCR2轴用于动脉粥样硬化保护
动脉粥样硬化是炎症性疾病,抗炎策略已在临床试验中显示可减少心血管事件,但靶向炎症小体-IL-1β-IL-6通路存在个体差异、未降低全因死亡率及感染风险。本文综述实验与人类数据,指出CCL2-CCR2轴调控炎性单核细胞迁移,是动脉粥样硬化治疗的新兴靶点,并讨论配体与受体靶向策略的机遇与挑战。
要点
- CCL2-CCR2轴调控炎性单核细胞在骨髓、循环和斑块间的迁移。
- 大规模遗传与观察性流行病学及人类斑块数据支持该轴在人动脉粥样硬化中的治疗潜力。
- 靶向该轴需权衡配体与受体策略,并关注通路内在的机遇与挑战。
核心结论
- CCL2-CCR2轴是心血管疾病中新兴的药物靶点,人类遗传与观察性数据支持其在动脉粥样硬化中的相关性及治疗潜力。
研究设计与样本
- 综述总结实验动脉粥样硬化模型、大规模遗传与观察性流行病学研究以及人类动脉粥样硬化斑块数据。
主要发现
- CCL2/MCP-1通过结合其同源受体CCR2协调炎性单核细胞在骨髓、循环和动脉粥样硬化斑块之间的转运。
- 一系列近期大规模遗传和观察性流行病学研究及人类斑块数据凸显CCL2-CCR2轴在人动脉粥样硬化中的相关性。
- 靶向炎症小体-IL-1β-IL-6通路的抗炎策略虽成功,但存在药物反应个体差异、未降低全因死亡率及感染率较高的问题。
临床怎么用
- CCL2-CCR2轴可作为动脉粥样硬化抗炎治疗的新兴靶点,但需在临床中权衡配体靶向与受体靶向策略。
局限性
- 靶向CCL2-CCR2轴在人类动脉粥样硬化疾病中的药理学干预存在通路内在的机遇与挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Decades of research have established atherosclerosis as an inflammatory disease. Only recently though, clinical trials provided proof-of-concept evidence for the efficacy of anti-inflammatory strategies with respect to cardiovascular events, thus offering a new paradigm for lowering residual vascular risk. Efforts to target the inflammasome-interleukin-1β-interleukin-6 pathway have been highly successful, but inter-individual variations in drug response, a lack of reduction in all-cause mortality, and a higher rate of infections also highlight the need for a second generation of anti-inflammatory agents targeting atherosclerosis-specific immune mechanisms while minimizing systemic side effects. CC-motif chemokine ligand 2/monocyte-chemoattractant protein-1 (CCL2/MCP-1) orchestrates inflammatory monocyte trafficking between the bone marrow, circulation, and atherosclerotic plaques by binding to its cognate receptor CCR2. Adding to a strong body of data from experimental atherosclerosis models, a coherent series of recent large-scale genetic and observational epidemiological studies along with data from human atherosclerotic plaques highlight the relevance and therapeutic potential of the CCL2-CCR2 axis in human atherosclerosis. Here, we summarize experimental and human data pinpointing the CCL2-CCR2 pathway as an emerging drug target in cardiovascular disease. Furthermore, we contextualize previous efforts to interfere with this pathway, scrutinize approaches of ligand targeting vs. receptor targeting, and discuss possible pathway-intrinsic opportunities and challenges related to pharmacological targeting of the CCL2-CCR2 axis in human atherosclerotic disease.
引用
- Georgakis MK, Bernhagen J, Heitman LH, et al. Targeting the CCL2-CCR2 axis for atheroprotection. Eur Heart J. 2022. PMID: 35567558. doi:10.1093/eurheartj/ehac094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。